UFIS-SWE-IG
0.1.0 - ci-build

UFIS-SWE-IG, published by UNICOM. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/ufis-swe-ig/ and changes regularly. See the Directory of published versions

Example Bundle: CBZEssPharm-125mg-Supp-SE-AJ-MPD-BBDL

Carbamazepine Essential Pharma 125 mg Suppositorium

MPID: SE-100013348-00011829
EURDID: 539

Full name: Carbamazepine Essential Pharma 125 mg Suppositorium

- Scientific Name Part: Name

- Strength part: 125 mg

- Pharmaceutical dose form part: Suppositorium

Name usage: Swedish (Kingdom of Sweden)

Authorised dose form: Suppository

Legal status of supply: Medicinal product subject to medical prescription

Domain: Human use

Resource status: Current

Product classification:

  • 100000097377 carbamazepine

Marketing Authorisation 1 of 1

Authorisation number: 11829

Region: Kingdom of Sweden

Marketing authorisation holder: Essential Pharma (M) Ltd

Identifier:

  • LOC-100038931

Status: Valid (1993-05-07)

Package 1 of 1

PCID:

Description:
Strip, 5 suppositorier

Marketing status:

  • Kingdom of Sweden: Marketed

Pack size:

  • 5 Suppository

Package: 1 Box (Cardboard)

Containing:

Package: 1 Strip (PolyPropylene) (Aluminium) (PolyEthylene)

Containing: 5 Suppository

Manufactured Item

Dose form: Suppository

Unit of presentation: Suppository

Ingredient

Role: Active

Substance: Carbamazepine

Presentation strength: 125 milligram(s) / 1 Suppository

Reference strength:
Carbamazepine 125 milligram(s) / 1 Suppository

Administrable Product (1 of 1)

Dose form: Suppository

Unit of presentation:

Route of administration:

  • Rectal use

Ingredients:

Ingredient

Role: Active

Substance: Carbamazepine

Presentation strength: 125 milligram(s) / 1 Suppository

Reference strength:
Carbamazepine 125 milligram(s) / 1 Suppository